Initial Management of Type 2 Diabetes in Patients with Chronic Kidney Disease

First-Line Therapy

• The KDIGO and ADA guidelines recommend initiating combination therapy with metformin and an SGLT2 inhibitor as first-line treatment for patients with type 2 diabetes and CKD, provided the patient's eGFR is ≥30 mL/min/1.73 m² for metformin and ≥20 mL/min/1.73 m² for the SGLT2 inhibitor 1, 2, 3, 4, 5
• This dual approach provides complementary mechanisms, with metformin addressing insulin resistance and SGLT2 inhibitors providing cardiorenal protection independent of glucose lowering 1, 3
• The combination of metformin and an SGLT2 inhibitor reduces mortality and morbidity benefits, including CKD progression, heart failure, and cardiovascular death 1, 5, 6

Dosing and Monitoring

• For patients with eGFR ≥60 mL/min/1.73 m², metformin can be started at 500 mg once daily or 850 mg once daily with meals, and titrated upward by 500 mg weekly or 850 mg every 2 weeks to a maximum of 2550 mg/day 1, 2
• For patients with eGFR 45-59 mL/min/1.73 m², metformin should be initiated at half the standard dose (500 mg daily) and titrated to a maximum of 1000-1500 mg daily 1, 2
• For patients with eGFR 30-44 mL/min/1.73 m², metformin should be initiated at 500 mg daily and the maximum dose should be 1000 mg daily 1, 2, 3, 5
• SGLT2 inhibitors can be initiated regardless of current glycemic control if eGFR is ≥20 mL/min/1.73 m², and should be chosen based on documented kidney and cardiovascular benefits 3, 4, 5

Additional Therapy

• If glycemic targets are not met with metformin and SGLT2 inhibitor, a GLP-1 receptor agonist should be added as the preferred third agent 1, 2, 3, 4
• GLP-1 receptor agonists provide additional cardiovascular benefits and weight loss, and long-acting formulations are preferred 1, 3, 5

Safety Monitoring

• Metformin-specific precautions include monitoring vitamin B12 levels if treatment exceeds 4 years, and holding metformin during acute illness causing dehydration or hypoperfusion 2, 3, 5
• SGLT2 inhibitor-specific precautions include educating patients on genital mycotic infections and diabetic ketoacidosis symptoms, and monitoring for volume depletion 1, 2

Contraindications and Alternatives

• If metformin or SGLT2 inhibitors are contraindicated, GLP-1 receptor agonists or DPP-4 inhibitors can be used as alternative oral agents, and insulin therapy may be necessary for advanced CKD 1, 3, 4, 7

Initial Oral Antidiabetic Therapy in Type 2 Diabetes with CKD (eGFR ≥ 30 mL/min/1.73 m²)

Metformin Use and Dosing

• Metformin is the foundational glucose‑lowering agent with a class 1B recommendation for patients with type 2 diabetes and chronic kidney disease, targeting insulin resistance and offering potential cardiovascular benefit. 8
• Dose adjustments by eGFR (Kidney International 2022):
  
  • eGFR 30–44 mL/min/1.73 m² – start 500 mg once daily; maximum 1 000 mg daily. 8

GLP‑1 Receptor Agonist as Third‑Line Therapy

• When HbA1c remains above target despite metformin + SGLT2‑inhibitor, a long‑acting GLP‑1 receptor agonist (e.g., dulaglutide, liraglutide, semaglutide) is the preferred add‑on agent. 8
• GLP‑1 receptor agonists provide additional cardiovascular protection, promote weight loss, and require no dose adjustment at any level of kidney function. 8
• Initiation should begin with low doses and gradual titration to reduce gastrointestinal adverse effects. 8

Monitoring Requirements

• Renal function: measure eGFR at least annually when eGFR ≥ 60 mL/min/1.73 m²; increase monitoring to every 3–6 months when eGFR < 60 mL/min/1.73 m². 8
• Vitamin B12: assess levels if metformin therapy exceeds four years to detect possible deficiency. 8

Metformin Dose Modification and Discontinuation

• If eGFR declines to 30–44 mL/min/1.73 m², reduce the metformin dose by half rather than stopping abruptly. 8
• Discontinue metformin completely when eGFR falls below 30 mL/min/1.73 m² because of a markedly increased risk of lactic acidosis. 8

Alternative Therapies When Metformin or SGLT2‑Inhibitors Are Contra‑indicated

• GLP‑1 receptor agonists become the preferred alternative oral/injectable option. 8
• DPP‑4 inhibitors, particularly linagliptin, are acceptable alternatives because they do not require dose adjustment in renal impairment. 8
• Sulfonylureas, thiazolidinediones, and α‑glucosidase inhibitors should be avoided as first‑line agents due to inferior cardiorenal outcomes. 8